Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03362931 | Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma | PHASE3 | COMPLETED | 65 | — | — | Jul 19, 2018 | Mar 18, 2022 | May 17, 2023 | 16 | Australia, Canada +4 |
IOP will be measured using a Goldmann applanation tonometer
| Arm | Type | Description |
|---|---|---|
| XEN45 Glaucoma Treatment System (hereafter referred to as XEN) | EXPERIMENTAL | XEN45 unilaterally implanted in the study eye |
| Name | Type | Description |
|---|---|---|
| XEN45 | DEVICE | XEN45 unilaterally implanted in the study eye |
Inclusion Criteria: Inclusion Criteria: - Diagnosis of ACG defined as areas of iridotrabecular contact present in ≥ 2 quadrants and glaucomatous damage to optic disc and visual field, in the study eye - Study eye has healthy, free, and mobile conjunctiva in the target quadrant Exclusion Criteria: -...